Targeting pharmaceutical agents to injured tissues
The present invention provides new compositions and methods to induce therapeutic angiogenesis locally utilizing a collagen binding domain to target an angiogenesis modulating agents. Fusion polypeptides containing a collagen binding domain linked to an angiogenesis modulating agent are provided, as are nucleic acid sequences encoding the fusion polypeptides. Also included are methods for locally altering circulation by administering a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or by administering a nucleic acid sequences encoding the fusion polypeptide. Tissue grafts in which isolated tissue is treated with a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or with a nucleic acid sequences encoding the fusion polypeptide are also provided, as are methods of making the grafts.
1. An isolated nucleic acid encoding a fusion polypeptide, wherein said fusion polypeptide comprises:
a) a collagen binding domain which binds exposed vascular collagen; and
b) an angiogenesis modulating domain, wherein said angiogenesis modulating domain directly effects endothelial cell proliferation.
2. The isolated nucleic acid of claim 1 , operably linked to a promoter.
3. An expression vector comprising the isolated nucleic acid of claim 2 .
4. The expression vector of claim 3 , wherein said expression vector is a retroviral vector.
5. A host cell comprising the isolated nucleic acid of claim 2 .
6. A method of producing a fusion polypeptide comprising:
(a) growing the host cells of claim 5 under conditions that allow expression of the nucleic acid; and
(b) recovering said fusion polypeptide.
7. The method of claim 6 , wherein the host is a prokaryotic cell.
8. The method of claim 6 , wherein the host is a eukaryotic cell.
9. The isolated nucleic acid of claim 1 , wherein said collagen binding domain is a collagen binding domain of von Willebrand Factor, or a conservative variation thereof which retains collagen binding activity.
10. The isolated nucleic acid of claim 9 , wherein said collagen binding domain comprises the decapeptide contained in SEQ ID NO:1.
11. The isolated nucleic acid of claim 1 , wherein said angiogenesis modulating domain is selected from the group consisting of, epidermal growth factor (EGF), hepatocyte growth factor (HGF), platelet derived endothelial cell growth factor (PD-ECGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), interleukin-8, a growth hormone, angiopoietin, acidic and basic fibroblast growth factors (FGFs), transforming growth factor alpha (TGF-α), vascular endothelial growth factor (VEGF), an enzyme, an enzymatic inhibitor, and an antibody.
12. An isolated nucleic acid encoding a fusion polypeptide, wherein said fusion polypeptide comprises:
a) a collagen binding domain of von Willebrand Factor, or a conservative variation thereof which retains collagen binding activity; and
b) an angiogenesis modulating domain that directly effects endothelial cell proliferation.
13. The isolated nucleic acid of claim 12 , wherein said collagen binding domain comprises the decapeptide contained in SEQ ID NO:1.
14. The isolated nucleic acid of claim 12 , wherein said angiogenesis modulating domain is selected from the group consisting of a growth factor, epidermal growth factor (EGF), hepatocyte growth factor (HGF), platelet derived endothelial cell growth factor (PD-ECGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), interleukin-8, a growth hormone, angiopoietin, acidic and basic fibroblast growth factors (FGFs), transforming growth factor alpha (TGF-α), vascular endothelial growth factor (VEGF), an enzyme, an enzymatic inhibitor, and an antibody.
15. An isolated nucleic acid encoding a polypeptide, wherein said fusion polypeptide comprises:
a) a collagen binding domain; and
b) an angiogenesis modulating domain that directly effects endothelial cell proliferation, wherein said domain is not derived from epidermal growth factor (EGF) or basic fibroblast growth factor (bEGF).
16. The isolated nucleic acid of claim 15 , wherein said collagen binding domain is a collagen binding domain of von Willebrand Factor, or a conservative variation thereof which retains collagen binding activity.
17. The isolated nucleic acid of claim 16 , wherein said collagen binding domain comprises the decapeptide contained in SEQ ID NO:1.
18. The isolated nucleic acid of claim 15 , wherein said angiogenesis modulating domain is selected from the group consisting of a growth factor, hepatocyte growth factor (HGF), platelet derived endothelial cell growth factor (PD-ECGF), platelet derived growth factor (PDGE), insulin-like growth factor (IGF), interleukin-8, a growth hormone, angiopoietin, acidic fibroblast growth factor (aFGF), transforming growth factor alpha (TGF-α), vascular endothelial growth factor (VEGF), an enzyme, an enzymatic inhibitor, and an antibody.
19. The isolated nucleic acid of claim 12 or claim 15 , operably linked to a promoter.
20. An expression vector comprising the isolated nucleic acid of claim 19 .
21. The expression vector of claim 20 , wherein said expression vector is a retroviral vector.
22. A host cell comprising the isolated nucleic acid of claim 19 .
23. A method of producing a fusion polypeptide comprising:
(a) growing the host cells of claim 22 under conditions that allow expression of the nucleic acid; and
(b) recovering said fusion polypeptide.
24. The method of claim 23 , wherein the host is a prokaryotic cell.
25. The method of claim 23 , wherein the host is a eukaryotic cell.